Detailed narrative
Stargardt Disease Program Update
Belite Bio announced positive top-line results from the Phase III DRAGON trial for Tinlarebant in Stargardt disease in December 2025. The trial met its primary efficacy endpoint, demonstrating a statistically significant and clinically meaningful 36% reduction in the growth rate of atrophic lesion, measured by definitely decreased autofluorescence, compared with placebo. This result positions the company favorably for regulatory engagement and commercialization. The DRAGON II study, designed for Japanese patients, reached its target enrollment of 60 subjects in January 2026, with 72 subjects enrolled as of February 27th, and final enrollment expected between 72-75.
Regulatory and Commercialization Strategy
The company's top priority is the NDA submission to the FDA in Q2 2026, which will be a rolling submission, pending the finalization of the Clinical Study Report this month. Commercialization preparations for Stargardt disease are well underway, with all key leadership positions hired. The company is actively building out its organization across sales, market access, medical affairs, marketing, regulatory, and operations. Belite Bio aims for a commercial launch of Tinlarebant in Stargardt disease by Q1 2027, with an initial sales team of 25-30 representatives.
Geographic Atrophy (GA) Program Progress
Enrollment for the Phase III PHOENIX trial in Geographic Atrophy (GA) has been completed with 400 subjects. An interim data look for the GA program is anticipated in the second half of 2026. Management believes that achieving a lesion growth inhibition of 15% to 20% with an oral compound would be considered a success, given that current injectable treatments show efficacy signals in the range of 13% to 21%. The oral nature of Tinlarebant could make it a standard of care if it reaches comparable efficacy thresholds.
Financial Position and Capital Allocation
Belite Bio significantly strengthened its financial position with a successful $402 million public offering in Q4 2025. This, along with other fundraising efforts, resulted in a robust cash, cash equivalent, U.S. treasury bills and notes balance of $772.6 million at the end of 2025, compared to $145.2 million at the end of 2024. The company projects approximately $150 million for R&D activities related to the existing pipeline and $200 million to $250 million for commercialization over the next three years, supporting its near and long-term objectives.
Pipeline Expansion and Pediatric Study
While prioritizing the Stargardt program, Belite Bio is also planning for pipeline expansion. An approved pediatric investigational plan (PIP) with WEMA is scheduled to initiate in April 2026. This two-year study will evaluate the safety and efficacy of Tinlarebant in children aged 3 to 11 years, aiming to establish a broader label beyond the initial adolescent and adult population. The company believes that treating younger patients before significant vision loss could provide substantial benefits.
International Regulatory Strategy
The company's primary focus for regulatory submissions is the FDA in the U.S., followed by the European Medicines Agency (EMA) and Japan's Pharmaceuticals and Medical Devices Agency (PMDA), and then China and other regions. Belite Bio is in constant communication with these authorities but is concentrating its resources on the U.S. submission to avoid diluting efforts, given the anticipated volume of questions from the FDA.